Affiliation:
1. Department of Tropical Medicine and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii
Abstract
ABSTRACT
Immunizations with
Plasmodium falciparum
MSP1-42 or MSP1-19 induce antibodies that inhibit parasites in vitro, which correlates with in vivo protective immunity by vaccination. We previously showed that several adjuvant formulations can induce anti-MSP1-19 antibodies in interleukin-6, intercellular adhesion molecule 1, CD80, and CD86 knockout (KO) mice and at levels similar to those obtained in the healthy uninfected hosts. Here, we determine whether these immune gene KOs or the immunopotentiating activities of the adjuvants have a more important influence on the induction of parasite-inhibitory anti-MSP1-19 antibodies. Results showed that the biological activities of the anti-MSP1-19 antibodies induced by these adjuvants were not affected by the immune gene KOs. All adjuvant formulations that induced significant inhibitory antibody responses (i.e., >50% inhibition of parasite growth) contained monophosphoryl lipid A (MPL) in emulsion carriers, whereas MPL or emulsion carriers alone were ineffective. The ability to retain vaccine efficacy by the MSP1-19 and adjuvant formulations in the altered immunological background is a valuable and significant attribute in light of many instances of skewed immune status in the targeted vaccine populations.
Publisher
American Society for Microbiology
Subject
Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy
Reference44 articles.
1. Agrawal, A., J. Lingappa, S. H. Leppla, S. Agrawal, A. Jabbar, C. Quinn, and B. Pulendran. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature424:329-334.
2. Angov, E., E. S. Bergman-Leitner, E. H. Duncan, A. Brent-Kirk, M. McCasland, R. Mease, L. Soisson, M.-A. Demoitie, B. R. Ogutu, D. G. Heppner, and J. A. Lyon. 2007. Measurement of antibody fine specificities induced by malaria vaccine FMP1/ASO2A from a pediatric phase 2B trial in western Kenya. Am. J. Trop. Med. Hyg.,vol. 77, issue 5 (Suppl.), abstr. 12.
3. Brady, C. P., R. L. Shimp, A. P. Miles, M. Whitmore, and A. W. Stowers. 2001. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris. Protein Expr. Purif.23:468-475.
4. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria
5. Chang, S. P., H. L. Gibson, C. T. Lee-Ng, P. J. Barr, and G. S. Hui. 1992. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J. Immunol.149:548-555.